Increased Expression of LRRK2, a Susceptibility Gene of IBD Results in Enhanced Pro-Inflammatory Response and Severe Experimental Colitis

Testsuya Takagawa, Masaki Tajima, Atsushi Kitani, Ivan J. Fuss and Warren Strober

> Mucosal Immunity Section Laboratory of Host Defenses NIAID/National Institutes of Health

Disclosure

Patent: Janssen Pharmaceuticals: The use of anti-IL-12p40 mAb for the treatment of Crohn's disease patients

LRRK2/MUC19 Locus has the Second Strongest Association with IBD in GWAS Studies

Crohn's disease	Ulcerative colitis	Total IBD
Gene Odds Ratio	Gene Odds Ratio	Gene Odds Ratio
1. IL23R 2.371	1. IL23R 1.682	1. IL23R 2.013
2. Nod2 1.557	2. HLA region 1.444	
	3. IL-10 1.277	3. Nod2 1.295
4. IRGM 1.324		4. IRGM 1.249
5. PTGER4 1.294		5. TAB1 1.209
6. TAB1 1.247		
7. ATG16L1 1.233		











PGN FSL-1 LPS Z)









LRRK2 Interacts with TAK1 Complex













BMDC from Lrrk2 Tg show increased NF-kB and MAP kinase in response to ZymD.











Summary



† Cytokines/inflammation ↓ Autophagy

Lrrk2 Tg mice display increased severity of colitis.

[©]LRRK2 thru Dectin-1 signaling interacts with TAK1 complex and activates NF-κβ signaling.

LRRK2 can bind and inactivate Beclin-1 resulting in decreased Autophagy.

Inhibitors of LRRK2 can ameliorate experimental inflammation.

Acknowledgements

Tetsuya TakagawaHyogo College of Medicine, JapanMasaki TajimaMucosal Immunity Section, NIH BeAtsushi KitaniMucosal Immunity Section, NIH Be Mucosal Immunity Section, NIH Bethesda MD Mucosal Immunity Section, NIH Bethesda MD

Warren Strober